etodolac has been researched along with Fatty Liver in 1 studies
Etodolac: A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).
etodolac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.
Fatty Liver: Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Etodolac was administered at a low (2 mg/kg) or high (10 mg/kg) dose three times a week for 16 months starting at the age of 3 months." | 1.33 | Chemoprevention of spontaneous development of hepatocellular carcinomas in fatty liver Shionogi mice by a cyclooxygenase-2 inhibitor. ( Cheng, J; Hada, T; Hirasawa, T; Imanishi, H; Inagaki, S; Iwamoto, Y; Liu, W; Nakamura, H; Nishiguchi, S; Shimomura, S; Tsujimura, T; Yamamoto, T, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, W | 1 |
| Nakamura, H | 1 |
| Tsujimura, T | 1 |
| Cheng, J | 1 |
| Yamamoto, T | 2 |
| Iwamoto, Y | 1 |
| Imanishi, H | 1 |
| Shimomura, S | 1 |
| Hirasawa, T | 1 |
| Inagaki, S | 1 |
| Nishiguchi, S | 1 |
| Hada, T | 1 |
1 other study available for etodolac and Fatty Liver
| Article | Year |
|---|---|
Chemoprevention of spontaneous development of hepatocellular carcinomas in fatty liver Shionogi mice by a cyclooxygenase-2 inhibitor.
Topics: Animals; Anticarcinogenic Agents; Chemoprevention; Cyclooxygenase 2 Inhibitors; Dinoprostone; Etodol | 2006 |